Does the unmet need hasten the review to 2 months- especially now with long term survival outcome data?- approve asap and treat a lethal disease.
FDA nowhere to hide, after delaying approval on a therapy that met its primary endpoint.
Reg
Ann: Long-Term Survival for Acute GvHD Treatment with Remestemcel, page-13
-
- There are more pages in this discussion • 343 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.49 |
Change
0.030(2.05%) |
Mkt cap ! $1.667B | |||
| Open | High | Low | Value | Volume |
| $1.48 | $1.50 | $1.48 | $810.7K | 544.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 5 | 9094 | $1.49 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.49 | 38103 | 4 |
View Market Depth
| Last trade - 10.26am 12/11/2024 (20 minute delay) ? |
| MSB (ASX) Chart |